Skip to main content

Table 1 Baseline characteristics of patients in the two groups

From: Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma

Characteristic

IMRT group (n = 62)

IMRT/chemotherapy group (n = 62)

P

Age

  

0.055

 ≤ 45 years

15 (24.2%)

25 (40.3%)

 

 > 45 years

47 (75.8%)

37 (59.7%)

 

Sex

  

1.000

 Male

44 (71.0%)

44 (71.0%)

 

 Female

18 (29.0%)

18 (29.0%)

 

Histology

  

0.144

 WHO type II

2 (3.2%)

6 (9.7%)

 

 WHO type III

60 (96.8%)

56 (90.3%)

 

T category

  

0.431

 T1

14 (22.6%)

18 (29.0%)

 

 T2

41 (66.1%)

34 (54.8%)

 

 T3

7 (11.3%)

10 (16.1%)

 

N category

  

0.701

 N0

21 (33.9%)

19 (30.6%)

 

 N1

41 (66.1%)

43 (69.4%)

 

TNM stage

  

0.433

 II

55 (88.7%)

52 (83.9%)

 

 III (T3N0M0)

7 (11.3%)

10 (16.1%)

 
  1. All data are n (%)
  2. IMRT Intensity-modulated radiotherapy, WHO World Health Organization